PortfoliosLab logoPortfoliosLab logo

ProShares UltraShort Nasdaq Biotechnology (BIS) Alternatives

ProShares UltraShort Nasdaq Biotechnology (BIS) belongs to the Leveraged Equities category. Below you'll find alternative ETFs from the same category, ranked by key criteria, plus funds that investors commonly compare with BIS. Use the tables to find lower-cost options, better risk-adjusted returns, or funds that fit a different role in your portfolio.

Cheapest Alternatives to BIS

BIS charges 0.95% annually. Among ETFs in the Leveraged Equities category, these options have the lowest expense ratios among BIS alternatives.


Best Risk-Adjusted Alternatives to BIS

Among ETFs in the Leveraged Equities category, these options rank highest on PortfoliosLab's risk-adjusted score, which accounts for volatility, drawdown, and return consistency over a 1-year period.


Top Performing BIS Alternatives (YTD)

BIS alternatives from the Leveraged Equities category, sorted by year-to-date return.


Lowest Volatility Alternatives to BIS

BIS alternatives from the Leveraged Equities category, sorted by annualized volatility over the past year.


Lowest Drawdown Alternatives to BIS

BIS alternatives from the Leveraged Equities category, sorted by maximum drawdown over the past year.


Other ETFs from ProShares

Most popular ProShares ETFs on PortfoliosLab, across asset classes.


Often Compared With BIS

What investors most often compare with BIS, based on PortfoliosLab usage data.


Compare BIS with Any Fund or Stock

Compare BIS with any ETF, mutual fund, or stock using PortfoliosLab's comparison tool.